Mullerian Biologics

Mullerian Biologics is a preclinical-stage biotechnology company dedicated to developing therapies based on the Mullerian Inhibiting Substance (MIS), also known as Anti-Mullerian Hormone (AMH). Spun out of Massachusetts General Hospital, the company focuses on the therapeutic potential of AMH in reproductive health and oncology. Their primary research involves using recombinant AMH to target the Anti-Mullerian hormone receptor type 2 (AMHR2) for treating ovarian cancer and endometriosis. Furthermore, the company is developing a first-in-class non-hormonal contraceptive that works by inhibiting follicle recruitment. The company leverages decades of research from the labs of its founders to translate developmental biology into clinical applications. Supported by organizations like the Bill & Melinda Gates Foundation, Mullerian Biologics aims to address significant unmet needs in women's health.